article thumbnail

Study Demonstrates Abelacimab Significantly Reduced Bleeding in Patients Regardless of Age, Bleeding Risk

DAIC

Patients with atrial fibrillation, particularly older patients, are frequently at a high risk of bleeding. In patients with atrial fibrillation, abelacimab reduced rates of bleeding relative to rivaroxaban regardless of bleeding risk, with greater absolute safety benefit in those at higher bleeding risk.

article thumbnail

Science behind the Study: Uncoupling Thrombosis and Hemostasis by Inhibiting Factor XI

The New England Journal of Medicine

in which a monoclonal antibody targeting factors XI and XIa was evaluated for its effects on bleeding events in patients with atrial fibrillation. This editorial describes the science behind a clinical trial reported by Ruff et al.

article thumbnail

Transhepatic Approach for Catheter Ablation of Atrial Fibrillation in Patients with Interrupted Inferior Vena Cava

HeartRhythm

Interruption of the inferior vena cava (IVC) is a rare vascular anomaly resulting from aberrant development during embryogenesis, deep venous thrombosis or extrinsic tumor compression.1 2-4 We aimed to describe the procedural steps, safety and efficacy of AF ablation using transhepatic access.

article thumbnail

The WATCHMAN, Left Atrial Appendage Occluder, and Device Related Thrombosis

Dr. Anish Koka

The left atrial appendage dangles off the left atrial chamber in the heart and has long been suspected of being a nidus for clot that can break off and cause a stroke. The treatment of patients with atrial fibrillation has always involved powerful blood thinners to prevent formation of clot.

article thumbnail

Management of complications associated with percutaneous left atrial appendage closure with or without ablation: experience from 512 cases over a 4-year period

Frontiers in Cardiovascular Medicine

BackgroundPercutaneous left atrial appendage closure (LAAC) serves as an alternative prophylactic strategy for patients with non-valvular atrial fibrillation (AF) who cannot undergo anti-coagulation therapy. The pericardial effusion or tamponade likely resulted from damage to the atrial appendage during LAAC device insertion.

article thumbnail

Epistaxis Versus Nonepistaxis Bleeding in Anticoagulated Patients With Atrial Fibrillation: Results From the ENGAGE AF‐TIMI 48 Trial

Journal of the American Heart Association

Bleeds were adjudicated using International Society on Thrombosis and Haemostasis criteria. Epistaxis events were less severe than nonepistaxis bleeds (International Society on Thrombosis and Haemostasis major: 3.2% Among 5247 patients with a bleeding event, 1008 (19.2%) had epistaxis and 4239 (80.8%) had nonepistaxis bleeding.

article thumbnail

Use of 3D echocardiography facilitates analysis of thrombolytic efficacy in patients with persistent atrial fibrillation

Journal of Cardiovascular Pharmacology

Abstract: This study seeks to identify the anticoagulant efficacy of rivaroxaban treatment on thrombi detected using echocardiography of the left atrial appendage in 275 patients with persistent atrial fibrillation (AF). 35.68, P=0.028) as factors related to left atrial appendage thrombus. P=0.008), 3D-EF (OR 6.4,